UCB's Global Corporate Website

This section is intended for media and financial analysts

Transparency Notification of Wellington management Company LLP

Participation on January 23, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), 27 January 2012 18:00 PM CET - regulated information - Wellington Management Company, LLP having its registered offices at 75 State Street, Boston, MA 02109, United States of America, sold a number of shares with voting rights on January 23, 2012 crossing down the threshold of 3% of UCB’s capital, the lowest statutory threshold for notification (5 505 950 shares on a total of 183,365,052 or 3%).

For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414,

Notes to the editor

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Asset Download

Stay up-to-date on the latest news and information from UCB